Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of previously untreated B-cell precursor acute lymphoblastic leukemia~  * More than 25% L1 or L2 lymphoblasts~ * No more than 25% L3 lymphoblasts~ * WBC \< 50,000/mm\^3~* No T-cell precursor acute lymphoblastic leukemia by immunophenotyping~* Massive lymphadenopathy, massive splenomegaly, or large mediastinal mass allowed~* CNS or testicular leukemia allowed~* No patients found to have t(8;14)(q24;q32), t(8;22)(q24;q11), and t(2;8)(p11-p12;q24) (characteristic of Burkitt's lymphoma)~PATIENT CHARACTERISTICS:~Age:~* 1 to 9~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No more than 72 hours since prior intrathecal cytarabine~Endocrine therapy:~* At least 30 days since prior systemic corticosteroids given for more than 48 hours~* Prior corticosteroids for mediastinal mass causing superior mediastinal syndrome allowed~* Prior or concurrent inhaled corticosteroids allowed~Radiotherapy:~* Prior radiotherapy for mediastinal mass causing superior mediastinal syndrome allowed~* No concurrent spinal radiotherapy~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Induction Not Randomized (Type: EXPERIMENTAL): Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
- Induction and Oral MTX, Double Delayed Intensification CNS (Type: EXPERIMENTAL): Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
- Induction and Augmented regimen (IV MTX, Double DI) (Type: EXPERIMENTAL): Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
- Induction and Oral MTX, Single Delayed Intensification (Type: EXPERIMENTAL): Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
- Induction and Oral MTX, Double Delayed Intensification (Type: EXPERIMENTAL): Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
- Induction and IV MTX, Single Delayed Intensification (Type: EXPERIMENTAL): Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
- Induction and IV MTX, Double Delayed Intensification (Type: EXPERIMENTAL): Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete